Editas Medicine, Inc. EDIT
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M |
| R&D | $90.0M | $199.2M | $177.7M | $175.0M | $142.5M | $158.0M | $96.9M | $90.7M | $83.2M | $57.0M |
| SG&A | $49.9M | $72.0M | $69.7M | $70.7M | $76.2M | $67.6M | $64.6M | $55.0M | $50.5M | $46.3M |
| Total operating expenses | $200.5M | $283.5M | $247.3M | $245.7M | $218.7M | $225.6M | $161.5M | $145.7M | $133.7M | $103.2M |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M | -$134.8M | -$140.9M | -$113.7M | -$119.9M | -$97.2M |
| Interest expense | $2.1M | $0 | — | — | — | — | — | — | — | — |
| Pre-tax income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M | -$116.0M | -$133.7M | -$110.0M | -$120.3M | -$97.2M |
| EPS, basic | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | — | — | — |
| EPS, diluted | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | -2.33 | -2.98 | -3.02 |
| Shares, diluted (wtd. avg.) | 88.7M | 82.3M | 76.0M | 68.7M | 67.6M | 58.6M | 50.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $146.6M | $131.5M | $127.5M | $141.5M | $207.4M | $143.6M | $239.8M | $136.4M | $148.2M | $186.9M |
| Short-term investments | $0 | $138.4M | $199.5M | $202.8M | $296.3M | $262.4M | $219.0M | $234.2M | $182.5M | — |
| Receivables | $15.2M | $16.3M | $10.2M | $5.1M | $267.0K | $6.0M | $418.0K | $30.0K | $679.0K | $88.0K |
| Total current assets | $163.9M | $289.3M | $340.8M | $356.8M | $507.3M | $419.1M | $463.8M | $374.8M | $332.2M | $187.2M |
| Property, plant and equipment | $3.5M | $14.5M | $12.0M | $15.6M | $17.1M | $14.0M | $10.9M | $40.2M | $39.4M | $40.4M |
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M | $572.6M | $508.9M | $420.4M | $373.3M | $229.2M |
| Accounts payable | $2.6M | $5.5M | $8.3M | $9.5M | $5.0M | $6.4M | $5.8M | $5.3M | $4.0M | $4.6M |
| Short-term debt | $5.0M | $5.0M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $46.2M | $77.2M | $63.2M | $60.1M | $46.9M | $58.2M | $60.0M | $35.9M | $36.7M | $33.1M |
| Long-term debt | $53.6M | $52.4M | $0 | — | — | — | — | — | — | — |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M | $179.0M | $246.4M | $184.2M | $165.2M | $94.6M |
| Retained earnings | -$1.63B | -$1.47B | -$1.23B | -$1.08B | -$857.7M | -$665.2M | -$549.2M | -$416.3M | -$305.9M | -$185.5M |
| Total equity | $27.3M | $134.3M | $349.1M | $360.7M | $553.6M | $393.6M | $262.4M | $236.2M | $208.1M | $134.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M | -$179.8M | -$40.7M | -$45.7M | -$9.4M | -$50.2M |
| Depreciation and amortisation | $5.3M | $5.8M | $6.1M | $6.3M | $5.1M | $4.0M | $2.8M | $3.3M | $2.7M | $1.2M |
| Stock-based compensation | $10.0M | $21.4M | $19.8M | $29.3M | $43.4M | $23.2M | $27.2M | $26.6M | $23.4M | $16.9M |
| Capital expenditure | $607.0K | $8.8M | $4.7M | $4.1M | $8.0M | $7.2M | $6.2M | $4.8M | $2.1M | $3.5M |
| Investing cash flow | $138.7M | $162.1M | -$3.7M | $114.1M | -$54.5M | -$140.5M | $12.3M | -$53.1M | -$183.8M | -$3.5M |
| Financing cash flow | $40.5M | $56.0M | $118.0M | $1.3M | $282.1M | $224.1M | $131.8M | $86.9M | $154.5M | $97.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001650664-26-000037.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$97.2M | -$120.3M | -$110.0M | -$133.7M | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |